VYNE Therapeutics (US:VYNE) Prnewswire·2025-12-17 21:35Core Viewpoint - Monteverde & Associates PC is investigating VYNE Therapeutics Inc. regarding its merger with Yarrow Bioscience, Inc., questioning the fairness of the deal where VYNE shareholders are expected to own 3% of the combined company [1]. Group 1: Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has recovered millions for shareholders [1]. - The firm is headquartered in the Empire State Building, New York City, and specializes in class action securities litigation [2]. Group 2: Legal Context - The firm emphasizes that no one is above the law and encourages shareholders with concerns to seek additional information [3]. - Monteverde & Associates PC has a successful track record in trial and appellate courts, including the U.S. Supreme Court [2].